Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Immune responses to AAV in clinical trials.

Mingozzi F, High KA.

Curr Gene Ther. 2007 Oct;7(5):316-24. Review.

PMID:
17979678
2.

Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy.

Michelfelder S, Lee MK, deLima-Hahn E, Wilmes T, Kaul F, Müller O, Kleinschmidt JA, Trepel M.

Exp Hematol. 2007 Dec;35(12):1766-76.

PMID:
17920758
4.
5.

Library selection and directed evolution approaches to engineering targeted viral vectors.

Jang JH, Lim KI, Schaffer DV.

Biotechnol Bioeng. 2007 Oct 15;98(3):515-24. Review.

PMID:
17614321
6.

Engineering adeno-associated virus for one-step purification via immobilized metal affinity chromatography.

Koerber JT, Jang JH, Yu JH, Kane RS, Schaffer DV.

Hum Gene Ther. 2007 Apr;18(4):367-78.

PMID:
17437357
7.

Immune responses to AAV capsid: are mice not humans after all?

Herzog RW.

Mol Ther. 2007 Apr;15(4):649-50. No abstract available.

PMID:
17372595
8.

A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8.

Akache B, Grimm D, Shen X, Fuess S, Yant SR, Glazer DS, Park J, Kay MA.

Mol Ther. 2007 Feb;15(2):330-9.

PMID:
17235311
9.

The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9.

Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA.

J Virol. 2006 Oct;80(19):9831-6.

11.

Isolation of targeted AAV2 vectors from novel virus display libraries.

Waterkamp DA, Müller OJ, Ying Y, Trepel M, Kleinschmidt JA.

J Gene Med. 2006 Nov;8(11):1307-19.

PMID:
16955542
12.

Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes.

Wu Z, Asokan A, Grieger JC, Govindasamy L, Agbandje-McKenna M, Samulski RJ.

J Virol. 2006 Nov;80(22):11393-7.

13.

Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry.

Asokan A, Hamra JB, Govindasamy L, Agbandje-McKenna M, Samulski RJ.

J Virol. 2006 Sep;80(18):8961-9.

15.

Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid.

Vandenberghe LH, Wang L, Somanathan S, Zhi Y, Figueredo J, Calcedo R, Sanmiguel J, Desai RA, Chen CS, Johnston J, Grant RL, Gao G, Wilson JM.

Nat Med. 2006 Aug;12(8):967-71.

PMID:
16845388
16.

Adeno-associated virus serotypes: vector toolkit for human gene therapy.

Wu Z, Asokan A, Samulski RJ.

Mol Ther. 2006 Sep;14(3):316-27. Review.

17.

Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism.

Perabo L, Goldnau D, White K, Endell J, Boucas J, Humme S, Work LM, Janicki H, Hallek M, Baker AH, Büning H.

J Virol. 2006 Jul;80(14):7265-9.

18.
19.

Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways.

Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA.

Nature. 2006 May 25;441(7092):537-41.

PMID:
16724069
20.

Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8.

Inagaki K, Fuess S, Storm TA, Gibson GA, Mctiernan CF, Kay MA, Nakai H.

Mol Ther. 2006 Jul;14(1):45-53.

Items per page

Supplemental Content

Support Center